Refractory Chronic Cough Improvement Via NAL ER (RIVER)
- Conditions
- Refractory Chronic Cough
- Interventions
- Drug: Nalbuphine ERDrug: Placebo
- Registration Number
- NCT05962151
- Lead Sponsor
- Trevi Therapeutics
- Brief Summary
A 2-period crossover study for the treatment of cough in patients with Refractory Chronic Cough via Nalbuphine ER (NAL ER). Each period will last 21 days and are separated by 21 days. Subjects will be randomized in Treatment Period 1 to either NAL ER or matching placebo and evaluated for 21 days. After completion of the first phase, subjects who received NAL ER will crossover to placebo and subjects who received placebo will crossover to NAL ER to complete Treatment Period 2.
For more information see the approved website: TheRiverTrial.com
- Detailed Description
A double-blind, randomized, placebo-controlled, 2-period crossover study for the treatment of cough with NAL ER in subjects with Refractory Chronic Cough.
Based on the screening cough monitor results, the study will enroll subjects in a 1:1 ratio to subgroups of 10-19 coughs/hour and ≥20 coughs/hour.
After meeting eligibility during the screening period, subjects will be randomly assigned to one of the following sequences:
* NAL ER in Treatment Period 1, followed by Placebo (PBO) in Treatment Period 2 OR
* PBO in Treatment Period 1, followed by NAL ER in Treatment Period 2.
Each treatment period lasts 21 days and are separated by a 21-day washout period. Subjects on NAL ER will have the dose titrated from 27 mg once a day (QD) to 108 mg twice a day (BID).
Study visits in each treatment period will be at Day -1 for Baseline cough assessments, and at Days 6, 13, and 20. Subjects will have blood drawn for pharmacokinetic (PK) analysis of nalbuphine plasma concentration. Subjects will also complete questionnaires for efficacy evaluations and undergo safety evaluations including an electrocardiogram (ECG).
At the Screening and Baseline visits and on Days 6, 13, and 20 during each treatment period, site staff will place an electronic cough monitor on the subject, which will be worn for a 24-hour recording period to assess cough frequency. At the end of each recording session (Days 7, 14, and 21), the monitor will be removed at home by the subject, and the subjects will complete Patient Reported Outcomes (PROs) questionnaires in the electronic diary.
Subjects will be taken off study drug at the end of Treatment Period 2 and followed off treatment for an additional 2 weeks.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Diagnosis of refractory chronic cough (RCC) for at least one year
- Chest radiograph or CT of thorax within 24 months or during screening not demonstrating any significant abnormalities contributing to RCC
- Diagnosis of sleep apnea
- Respiratory tract infection within 6 weeks of Baseline
- History of bronchiectasis, COPD, or IPF
- History of uncontrolled asthma
- Current smokers/vapers, quit smoking with <=12 months, using nicotine supplements, or history of >=20 pack years
- History of major psychiatric disorder
- History of substance abuse
- Pregnant or lactating females
- Known intolerance to opioids
- Abnormal kidney or liver functions based on Screening lab results.
- Known hypersensitivity to nalbuphine or to NAL ER excipients
- Previous participation in a nalbuphine ER clinical study
- Use of opiates, benzodiazepines, or MAOIs within 14 days of Baseline
- Use of pregabalin, gabapentin, thalidomide for treatment of cough within 14 days of Baseline
- Use of ACE inhibitors within 12 weeks of Baseline
- Use of a medication having a "known risk" of Torsade de Pointes (categorized as "KR" on the Credible Meds® website.) 4 weeks prior to Baseline
- Use of unstable doses of medications associated with a potential risk of QT prolongation but not clearly associated with Torsade de Pointes within 4 weeks of screening.
- Use of unstable doses of cough suppressants within 14 days of Baseline
- Use of unstable doses of medications that affect serotonergic neurotransmission that may cause serotonin syndrome with opioids within14 days of Baseline
- Use of unstable doses of P450 isozyme inhibitors/inducers within 14 days of Baseline
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description NAL ER Nalbuphine ER NAL ER, tablets, 27 mg QD to BID, 54 mg BID, 108 mg BID Placebo Placebo Placebo, tablets, 0 mg QD to BID, 0 mg BID, 0 mg BID
- Primary Outcome Measures
Name Time Method 24 hr cough frequency Day 21 versus Baseline Relative change in frequency (coughs per hour) versus Placebo
- Secondary Outcome Measures
Name Time Method Sleep cough frequency Days 7, 14, and 21 versus Baseline Relative change in frequency (coughs per hour) versus Placebo
Leicester Cough Questionnaire Day 21 versus Baseline 19 item questionnaire with a grading of 1 (all the time ) to 7 (none of the time) versus Placebo
Number of participants with treatment related adverse events, as assessed by CTCAE v.5.0 Baseline through follow-up Adverse events, clinical labs, vital signs, physical exams, electrocardiograms
Subjective Opiate Withdrawal Scale Daily for 14 days after last dose in Period 2 16 item questionnaire for 14 days following last dose of study drug
24 hour cough frequency Days 7, 14, and 21 versus Baseline Proportion of responders with \>=30%, 50% and 75% reduction in frequency versus Placebo
Awake cough frequency Days 7, 14, and 21 versus Baseline Relative change in frequency (coughs per hour) versus Placebo
Cough Severity Visual Analogue Scale Days 7, 14, and 21 versus Baseline 1 item scale with minimum score of 0 (no cough) to 10 (worst cough) versus Placebo
Patient-Reported Cough Frequency (change) Days 7, 14, and 21 versus Baseline Change versus Placebo
Patient Global Impression of Cough Severity Days 7, 14, and 21 versus Baseline 1 item question with a grading from "no cough, to mild, moderate or severe" versus Placebo
Patient Global Impression of Cough Change Days 7, 14, and 21 versus Baseline 1 item question with a 7 point grading from "much better to much worse" versus Placebo
Clinicians Global Impression of Cough Change Day 21 versus Baseline (both treatment periods) 1 item question with a 7 point grading from "very much improved to very much worse" versus Placebo
Clinicians Global Impression of Cough Severity Day 21 versus Baseline (both treatment periods) 1 item question with a grading from "no cough, to mild, moderate or severe" versus Placebo
Patient-Reported Cough Frequency (proportion) Days 7, 14, and 21 versus Baseline Proportion of responders with improvement in at least one category versus Placebo
Trial Locations
- Locations (14)
McMaster University Medical Centre
🇨🇦Hamilton, Ontario, Canada
Inspiration Research
🇨🇦Toronto, Ontario, Canada
CIC Mauricie Inc.
🇨🇦Trois-Rivières, Quebec, Canada
Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital
🇬🇧Cottingham, East Riding Of Yorkshire, United Kingdom
Kings College Hospital NHS Foundation Trust
🇬🇧London, Greater London, United Kingdom
University Hospital of South Manchester NHS Foundation Trust (UHSM) - Wythenshawe Hospital
🇬🇧Manchester, Greater Manchester, United Kingdom
Accellacare South London
🇬🇧Sidcup, Kent, United Kingdom
Accellacare North London
🇬🇧Northwood, Middlesex, United Kingdom
Accellacare Northamptonshire
🇬🇧Corby, Northamptonshire, United Kingdom
Belfast City Hospital
🇬🇧Belfast, Northern Ireland, United Kingdom
North Tyneside General Hospital - Northumbria Healthcare NHS Foundation Trust
🇬🇧North Shields, Tynemouth, United Kingdom
Accellacare Warwickshire
🇬🇧Coventry, Warwickshire, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
🇬🇧Birmingham, West Midlands, United Kingdom
Accellacare Yorkshire
🇬🇧Shipley, Yorkshire, United Kingdom
Related News
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
- Prev
- 1
- Next